Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
95 Results for "
L929
" in MedChemExpress (MCE) Product Catalog:
Products (95)
95 Results for "L929" in MCE Product Catalog:
8
8 Publications Verification
Synonyms: GSK'843
Target:
Research Areas:
GSK-843 (GSK'843) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 8.6 nM, and inhibits kinase activity with an IC50 of 6.5 nM. GSK-843 can be used for the research of inflammation .
3
3
3 Cited Publications
Synonyms: Hexamethylene amiloride; HMA
Target:
5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na +/H + exchanger inhibitor, which decreases the intracellular pH (pHi) and induces apoptosis in leukemic cells. 5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) is also an inhibitor of the HIV-1 Vpu virus ion channel and inhibits mouse hepatitis virus (MHV) replication and human coronavirus 229E (HCoV229E) replication in cultured L929 cells with EC50s of 3.91 μM and 1.34 μM, respectively .
2
Target:
Research Areas:
Hydroxylamine (50% w/w in water) is an inorganic highly reactive compound and antibacterial agent. Hydroxylamine (50% w/w in water) acutely activates the transport activity of GLUT1, inhibits Monoamine oxidase activity. Hydroxylamine (50% w/w in water) inhibits nitrite oxidizing bacteria. Hydroxylamine (50% w/w in water) activates glucose uptake. Hydroxylamine (50% w/w in water) can be used in the research of inflammatory diseases and allergies[1][2][3][4] .
1
1 Cited Publications
Cat. No.: HY-W140974
CAS No.: 727699-84-5
SN-001 is a STING inhibitor with an IC50 of 3.82 μM .
1
1 Cited Publications
Cat. No.: HY-171658
CAS No.: 3070346-91-4
Research Areas:
R1-ICR-5 is a highly selective RIPK1 PROTAC degrader. Mediated by VHL, R1-ICR-5 induces the degradation of RIPK1, which in turn dysregulates the TNFR1 and TLR3/4 signaling hubs, enhances the signaling outputs of NF-κB, MAPK and IFN, and simultaneously promotes RIPK3 activation and necroptosis (necroptosis). R1-ICR-5 can be used in the research of triple-negative breast cancer and skin inflammation .
1
1 Cited Publications
Cat. No.: HY-137709A
Target:
Research Areas:
2'2'-cGAMP disodium, a synthetic CDN, binds STING in the immune response, inducing IFN-β. 2'2'-cGAMP disodium binds weaker binding to STING than 2'3'-cGAMP (HY-100564) but stronger than other CDNs .
Cat. No.: HY-L929
2,527 compounds
In drug discovery and development (R&D) area, target binding and druggability optimization are core processes. Among these attributes, high solubility is critical for a compound to achieve druggability, as it directly impacts the progress of drug R&D. Superior solubility ensures the rapid dissolution and uniform distribution of drug molecules in vivo, thereby enhancing bioavailability and effectively mitigating issues such as suboptimal efficacy, increased dosage requirements, or exacerbated toxic and side effects arising from insufficient solubility.
From the perspective of medicinal chemistry, high-solubility drug fragments serve as high-quality "molecular building blocks". Based on these fragments, lead compounds with potential druggability can be rapidly screened out, which significantly shortens the drug R&D cycle and reduces R&D costs. Meanwhile, the high-solubility drug fragment library can provide diverse options for drug development in different therapeutic areas, offer solutions for the solubility defects of existing clinical drugs, and facilitate the development of novel, highly effective targeted drugs with higher bioavailability and better safety profiles.
MCE has collected and compiled 2,527 experimentally validated small-molecule fragments with high solubility. These fragments can be directly used for drug molecular design, providing high-quality pre-validated solubility fragments that significantly improve the efficiency of lead compound screening and accelerate the progress of drug R&D.
Cat. No.: HY-P99796
CAS No.: 1167985-17-2
Synonyms: ATN-103; PF-5230896
Target:
Research Areas:
Cat. No.: HY-W004761
CAS No.: 13675-18-8
Synonyms: Hypodiboric acid
Cat. No.: HY-152846
CAS No.: 2268739-68-8
Synonyms: GDC-8264
Target:
Research Areas:
Cardiovascular Disease Inflammation/Immunology Endocrinology
Flizasertib (GDC-8264) is an orally active, reversible and selective RIP1 inhibitor with Ki app values of 0.00071 μM and 0.0013 μM for human and cynomolgus monkey RIP1 kinase, respectively. Flizasertib blocks RIP1 autophosphorylation but does not affect RIP1 protein stability. Flizasertib inhibits pro-inflammatory cytokines (CCL3, CCL4, and IL-1β) production. Flizasertib results in inhibition of colitis and ileitis. Flizasertib can be used in the research of cardiac surgery-associated acute kidney injury .
Cat. No.: HY-N3266
CAS No.: 99353-00-1
Cat. No.: HY-161247
CAS No.: 2641482-08-6
Target:
Research Areas:
5HT2A antagonist 2 is an orally active, selective antagonist for 5HT2A with IC50 of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .
Cat. No.: HY-170872
Target:
Research Areas:
PT-129 is a G3BP1/G3BP2 PROTAC degrader. PT-129 inhibits the formation of stress granules, disassembles pre-existing stress granules, disrupts stress granule-mediated ATF4 trafficking via migratory exocytosis, and suppresses cancer cell proliferation. PT-129 is applicable to the research of lung cancer and melanoma .
Cat. No.: HY-134467
CAS No.: 98570-83-3
Target:
Cat. No.: HY-W250121
CAS No.: 9000-65-1
Cat. No.: HY-W391506
CAS No.: 9011-14-7
Synonyms: Poly(methyl methacrylate), beads; PMMA
Research Areas:
Poly (methyl methacrylate) (Poly(methyl methacrylate), beads; PMMA) is an amorphous glassy acrylic thermoplastic polymer belonging to the acrylate family, synthesized from methyl methacrylate monomers. Poly (methyl methacrylate) drives biochemical processes including free volume expansion induced by inelastic deformation, yield stress and strain softening regulated by physical aging, acid hydrolysis to polymethacrylic acid, multi-stage combustion, oxygen-dependent thermal decomposition, primary amine-mediated polypentanimide formation, and grafting/crosslinking-based copolymer and composite formation. Poly (methyl methacrylate) exhibits histocompatibility, low toxicity, low inflammatory potential, and fracture resistance; it can form functional blends and composites for biomedical and dental applications; it also allows performance-enhancing chemical and mechanical modifications. Poly (methyl methacrylate) is applicable to studies related to cranial repair .
Cat. No.: HY-W196368
CAS No.: 2217-60-9
Category:
Cat. No.: HY-170949
CAS No.: 2925028-15-3
Target:
Research Areas:
STING-IN-11 (Compound 42) is an orally active STING inhibitor with an IC50 of 37.8 nM. STING-IN-11 can block the palmitoylation of the STING protein and STING downstream signaling, and inhibit STING-mediated inflammation. STING-IN-11 has good in vivo safety and can be used for the research of STING-related inflammatory and autoimmune diseases .
Cat. No.: HY-W749867
CAS No.: 6766-87-6
Synonyms: Calcium disodium EDTA dihydrate
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
